Drug Type Biosimilar, Monoclonal antibody |
Synonyms Palivizumab Biosimilar (Mabpharm Ltd.), 帕利珠单抗生物类似药(迈博药业有限公司) |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Preclinical | China | 20 May 2019 |